08:37 AM EST, 12/23/2024 (MT Newswires) -- Nuvation Bio ( NUVB ) said Monday the US Food and Drug Administration has accepted its new drug application for drug candidate taletrectinib intended for the treatment of non-small cell lung cancer.

The FDA granted priority review and set a Prescription Drug User Fee Act goal date of June 23, Nuvation said.

Nuvation stock was up more than 4% in recent premarket activity.

Price: 2.80, Change: +0.12, Percent Change: +4.48